It was another difficult week for U.S. stocks, as global uncertainties and a weak job report kept markets from making too much headway this week. Precious metals and oil held their own at week’s end, but there was still a great deal of day-to-day volatility among those prices.
A number of sub-$5 stocks were bouncing around hard this week. The diversity was lacking — biotech and other health-related issues continued to dominate among smaller stocks — but nonetheless, there were a few exciting moves to be found:
Here are the best stocks under $5 for this week:
Best Stocks Under $5: Lee Enterprises, Incorporated (LEE)
10/02/15 Closing Price: $ 2.28 (+30% for the week)
Lee Enterprises, Incorporated (NYSE:LEE) is a midwest and far west provider of local news, information and advertising, including 50 daily newspaper markets.
This week, LEE presented a review of its business at the Deutsche Bank Conference, in Scottsdale, Arizona. The key speakers included Chairman and CEO, Mary Junck, Kevin Mowbray, Executive VP and COO, and Ron Mayo, VP, CFO, and treasurer.
Among the accomplishments cited by the group were strong digital revenue growth, subscription growth, strong cash flow, and long-term refinancing to reduce debt. The company also expects to grow EBITDA in Q4.
LEE stock has underperformed the broader markets for the past two years.
Best Stocks Under $5: Bill Barrett Corporation (BBG)
10/02/15 Closing Price: $4.12 (+21% for the week)
Bill Barrett Corporation (NYSE:BBG) is an energy company that develops and explores for oil and natural gas in various regions of Colorado and Wyoming, and Utah.
Earlier this week, Bill Barrett had good news on two different fronts. Its $375 million credit line was reaffirmed by its lenders, and the company said it has reached a deal to sell non-core Uinta Basin property assets in Utah for $27 million, to an unnamed buyer as of now, along with making spending cuts for the remainder of 2015. These moves are being done to combat the reduced prices for both oil and natural gas this year.
BBG stock is off nearly 80% in the past 52 weeks.
Best Stocks Under $5: Myos Corp (MYOS)
10/02/15 Closing Price: $3.32 (+25% for the week)
MYOS Corp (NASDAQ:MYOS), a bionutrition and biotherapeutics company, surged this week despite an earnings report that seems to suggest the company is going backward. While EPS did improve from a loss of 34 cents a year ago to a loss of 30 cents this quarter, revenue declined from $1.68 million to $0.08 million. Several other fundamental categories were also weaker than a year ago.
What may have helped the company more this week was the appointment of Robert Hariri to the board of Cryoport, Inc. (NASDAQ:CYRX). Hariri currently also serves on the board of MYOS, so perhaps this will become a networking opportunity for MYOS over the long term.
MYOS stock has been all over the board lately. It fell from $6.50 a share in May to a recent low near $1.50, but has \more than doubled over the last two weeks.
Investors are urged to use caution when entering positions.
Best Stocks Under $5: Sequenom, Inc. (SQNM)
10/02/15 Closing Price: $2.13 (+13% for the week)
Sequenom, Inc. (NASDAQ:SQNM) specializes in pre-natal healthcare, developing molecular based laboratory tests to spot potential problems early on. They also focus on genetic testing solutions and genetic counseling.
On Monday, SQNM hosted a 2015 investor and analyst day in New York City, and presented a discussion of their corporate future vision and plans for testing in the areas of reproductive health and oncology.
One of the highlighted products of the seminar was Sequenom’s materniT21 PLUS, a non-invasive prenatal test to detect fetal chromosomal abnormalities.
SQNM, like many other small biotech firms, has had a rough go lately, falling from $4.25 in May to a recent low around $1.75. But investor and analyst days like the one this week can bring positive attention to the company.
Best Stocks Under $5: Parnell Pharmaceuticals Holdings Ltd (PARN)
10/02/15 Closing Price: $4.00 (+16% for the week)
Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN) is an Australian company that manufacturers and sells health products for animals.
It was a solid week for PARN stock, which was recently given a “strong buy” rating by Zacks Investment Research. Robert Joseph, President and Chief Executive Officer presented at the Ladenburg Thalmann 2015 Healthcare Conference, which was held in New York City on Tuesday.
At the conference, Joseph discussed several key points that should grow the company in the future. He cited bringing Zydex and Glyde, two natural canine arthritis products, to large markets, the establishment of sales teams of 40 territory managers who will cover 12,000 clinics, and triple-digit sales growth in Parnell’s U.S. production of animal business.
PARN stock has been cut in half since July 2014, so perhaps this week’s improved action may signify that the stock has finally put in a bottom.
As of this writing, Ethan Roberts does not hold a position in any of the aforementioned securities.